ES2064327T3 - Uso de icam-1 o de sus derivados funcionales para el tratamiento de una inflamacion no especifica. - Google Patents

Uso de icam-1 o de sus derivados funcionales para el tratamiento de una inflamacion no especifica.

Info

Publication number
ES2064327T3
ES2064327T3 ES88106902T ES88106902T ES2064327T3 ES 2064327 T3 ES2064327 T3 ES 2064327T3 ES 88106902 T ES88106902 T ES 88106902T ES 88106902 T ES88106902 T ES 88106902T ES 2064327 T3 ES2064327 T3 ES 2064327T3
Authority
ES
Spain
Prior art keywords
icam
treatment
functional derivatives
specific inflammation
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88106902T
Other languages
English (en)
Inventor
Donald Carroll Anderson
Robert Rothlein
Clinton Wayne Smith
Randall Wilbur Barton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Baylor College of Medicine
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Baylor College of Medicine
Application granted granted Critical
Publication of ES2064327T3 publication Critical patent/ES2064327T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

EL INVENTO PROVEE UN METODO PARA TRATAR LA INFLAMACION CAUSADA POR EL SISTEMA DE DEFENSA NO ESPECIFICA DE UN SUJETO MAMIFERO. LA INFLAMACION ES TRATADA POR PROVEER AL SUJETO CON UN AGENTE ANTI-INFLAMATORIO CAPAZ DE INHIBIR LA ADHESION DE CELULAS ENDOTELIALES GRANULOCITAS.
ES88106902T 1987-11-02 1988-04-29 Uso de icam-1 o de sus derivados funcionales para el tratamiento de una inflamacion no especifica. Expired - Lifetime ES2064327T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11579787A 1987-11-02 1987-11-02

Publications (1)

Publication Number Publication Date
ES2064327T3 true ES2064327T3 (es) 1995-02-01

Family

ID=22363440

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88106902T Expired - Lifetime ES2064327T3 (es) 1987-11-02 1988-04-29 Uso de icam-1 o de sus derivados funcionales para el tratamiento de una inflamacion no especifica.

Country Status (10)

Country Link
EP (1) EP0314863B1 (es)
JP (1) JP2710627B2 (es)
AT (1) ATE114972T1 (es)
AU (2) AU1550988A (es)
CA (1) CA1331132C (es)
DE (1) DE3852374T2 (es)
DK (1) DK175491B1 (es)
ES (1) ES2064327T3 (es)
GR (1) GR3015298T3 (es)
ZA (1) ZA883160B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
AU4412889A (en) * 1988-09-28 1990-04-18 Dana-Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5235049A (en) * 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
CA2008368C (en) * 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
NO900155L (no) * 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
DK0387701T3 (da) * 1989-03-09 1992-12-07 Boehringer Ingelheim Pharma Anvendelse af intercellulære adhæsionsmolekyler samt deres bindende ligander ved behandling af astma
ES2095876T3 (es) * 1989-06-02 1997-03-01 Univ Johns Hopkins Med Anticuerpos monoclonales contra la cadena beta de receptores de adhesion de leucocitos; procedimiento de produccion de estos anticuerpos y utilizacion
EP0438312A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Recombinant human anti-cd18 antibodies
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
WO1991018010A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof
WO1991018011A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
DE4019024A1 (de) * 1990-06-14 1991-12-19 Bayer Ag Verwendung der efomycine a, e und g als entzuendungshemmende mittel
DK162890D0 (da) * 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
ES2134762T3 (es) * 1990-07-20 1999-10-16 Bayer Ag Formas multimericas de proteinas receptoras de rinovirus humanos.
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
DE69129460T2 (de) * 1990-08-31 1998-10-15 Boehringer Ingelheim Pharma Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
AU9055091A (en) * 1990-11-08 1992-06-11 Biogen, Inc. Treatment for inflammatory bowel disease
WO1992009293A1 (en) * 1990-11-23 1992-06-11 The General Hospital Corporation Inhibition of cell adhesion protein-carbohydrate interactions
US5288854A (en) * 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
US5223396A (en) * 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
US5891841A (en) * 1991-06-11 1999-04-06 The Center For Blood Research, Inc. Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
AU667487B2 (en) * 1991-10-01 1996-03-28 General Hospital Corporation, The Preventing allograft rejection with antibodies to adhesion molecules
JP3679112B2 (ja) * 1991-10-04 2005-08-03 アメリカ合衆国 細胞接着分子の遮断による眼の炎症の治療
GB9126918D0 (en) * 1991-12-19 1992-02-19 Univ London Members of specific binding pairs;methods of their making and using
EP0578819A4 (en) * 1992-01-27 1994-10-12 Icos Corp Icam-related protein.
US6100383A (en) * 1992-01-27 2000-08-08 Icos Corporation Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US6153395A (en) * 1992-01-27 2000-11-28 Icos Corporation ICAM-related protein
US5525487A (en) * 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
US5532127A (en) * 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
US5773218A (en) * 1992-01-27 1998-06-30 Icos Corporation Method to identify compounds which modulate ICAM-related protein interactions
US5989843A (en) * 1992-01-27 1999-11-23 Icos Corporation Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
US6818743B1 (en) 1992-01-27 2004-11-16 Icos Corporation I-CAM related protein
CA2129637C (en) * 1992-02-12 1999-05-04 Roy R. Lobb Treatment for inflammatory bowel disease
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
WO1993017047A1 (en) * 1992-02-28 1993-09-02 Board Of Regents, The University Of Texas System Compositions and methods for the treatment of thermal injury
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
DE4335273A1 (de) * 1993-10-15 1995-04-20 Univ Ludwigs Albert Peptide zur Tumortherapie
US5679340A (en) * 1994-03-31 1997-10-21 Diacrin, Inc. Cells with multiple altered epitopes on a surface antigen for use in transplantation
WO1995027736A1 (en) * 1994-04-12 1995-10-19 Boehringer Ingelheim Pharmaceuticals, Inc. Use of agents which block intercellular adhesion molecule/receptor interaction in the treatment of respiratory viral infection
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
JP5105578B2 (ja) 2003-11-05 2012-12-26 サーコード バイオサイエンス インコーポレイテッド 細胞接着のモジュレーター
US8168655B2 (en) 2005-05-17 2012-05-01 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
SI3715345T1 (sl) 2012-07-25 2024-07-31 Bausch + Lomb Ireland Limited Priprava zaviralca lfa-1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE128727T1 (de) * 1987-05-04 1995-10-15 Dana Farber Cancer Inst Inc Interzellulare adhäsions-moleküle und deren bindungsliganden.

Also Published As

Publication number Publication date
JP2710627B2 (ja) 1998-02-10
DE3852374D1 (de) 1995-01-19
EP0314863A2 (en) 1989-05-10
DK239388A (da) 1989-05-03
AU622120B2 (en) 1992-04-02
AU2633388A (en) 1989-07-27
DE3852374T2 (de) 1995-05-04
DK239388D0 (da) 1988-05-03
JPH01135724A (ja) 1989-05-29
EP0314863A3 (en) 1990-04-04
ATE114972T1 (de) 1994-12-15
GR3015298T3 (en) 1995-06-30
AU1550988A (en) 1989-07-27
EP0314863B1 (en) 1994-12-07
ZA883160B (en) 1990-02-28
DK175491B1 (da) 2004-11-08
CA1331132C (en) 1994-08-02

Similar Documents

Publication Publication Date Title
GR3015298T3 (en) Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation.
ES494356A0 (es) Procedimiento para el tratamiento de superficies hidrofobas
ES2058423T3 (es) Composicion de factor de crecimiento de fibroblastos, resistente a los acidos, para tratar enfermedades ulcerantes del tracto gastrointestinal.
ES540645A0 (es) Aparato para el tratamiento del plasma.
ES493614A0 (es) Metodo para el control de tejidos y-o liquidos bioligicos
MX157191A (es) Procedimiento para el tratamiento de aceites usados
DE3860201D1 (de) Entzuendungshemmende agentien.
ES2013631B3 (es) Metodo para el tratamiento de tejidos.
ES2059301T3 (es) Utilizacion de inhibidores de la enzima convertidora de angiotensina para el tratamiento de la aterosclerosis, trombosis y de la enfermedad vascular periferica.
ES520914A0 (es) Procedimiento para el tratamiento de lodos industriales residuales.
ES511280A0 (es) "aparato y metodo perfeccionados para el tratamiento de lodos de aguas residuales".
ES2017764B3 (es) Procedimiento para el tratamiento de celulas primarias utilizadas
ES486598A0 (es) Procedimiento para el tratamiento de acero que contiene boropara la colada continua
ES250665Y (es) Bombo para el tratamiento de pieles y cueros
ES554903A0 (es) Disposicion para el tratamiento de piezas de trabajo
ES2014409B3 (es) Procedimiento para el acabado de superficies de laminas
ES495696A0 (es) Procedimiento e instalacion para el tratamiento de gases
ES555832A0 (es) Procedimiento y dispositivo para el tratamiento de desechos situados solidos no organicos
ES540016A0 (es) Procedimiento para el tratamiento de acero poco aleado para un emparejado de materiales
ES2019262A4 (es) Procedimiento para el tratamiento biologico de nitratos disueltos
FI882219A7 (fi) Menetelmä nitraattia ja/tai nitriittiä sisältävän jäteveden puhdistami seksi.
ES2053452T3 (es) Antibioticos de 1-carbacefalosporina.
ES543582A0 (es) Perfeccionamientos en los batanes para el tratamiento de pieles y similares
AR230845A1 (es) Procedimiento para el tratamiento de sustratos de acero o de acero galvanizado
ES549671A0 (es) Procedimiento de obtencion de composiciones para el trata- miento de infecciones por rinovirus

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 314863

Country of ref document: ES